Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883032 · ClinicalTrials.gov registry record · NA
Investigation of the Accuracy of an Automated Refractor to Provide Well-tolerated Eyeglass Prescriptions
A NA study of Refractive Errors, sponsored by PlenOptika.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT06883032: Completed NA study of Refractive Errors, sponsored by PlenOptika.
NCT06883032 is a NA study of Refractive Errors that has completed, run by PlenOptika. The registered enrollment target is 92 participants, roughly in line with the 100-participant average among 14 other Refractive Errors trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06883032, a NA study of Refractive Errors, has completed, sponsored by PlenOptika.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
At the New England College of Optometry in Boston, MA, subjects ages 18-65 who have received or are receiving treatment for refractive error who choose to enroll in the study will be evaluated using subjective refraction and automated refraction, by way of the QuickSee Plus refractor. Subjects will then be randomized into one of two treatment plans: receive glasses from automated refraction first then subjective refraction second, and vice versa. After one week of wearing the first pair of glasses, patient preferences are assessed, and glasses are switched. After a week of wearing the second pair of glasses from the alternate measurement method, patient preferences are again assessed. Patients may then decide which pair patient like best. This is a triple blind, case-crossover clinical trial.
Primary Outcome
Patients are asked the question "Which eyeglasses did you prefer?". Patient response is then recorded.
Conditions Studied
Interventions
- OTHER AR Eyeglasses first, SR Eyeglasses second
- OTHER SR Eyeglasses first, AR Eyeglasses second
Study Locations (1)
Massachusetts
- New England College of Optometry (NECO) Center for Eye Care of Commonwealth - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-02-16 |
| Est. Completion | 2025-02-28 |
| Phase | NA |
What the finished NCT06883032 record still lists
NCT06883032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, roughly in line with the 100-participant average among 14 other Refractive Errors trials with a reported enrollment target.
The record links to 1 condition, with Refractive Errors appearing as the primary indexed condition, and to 2 interventions - of which AR Eyeglasses first, SR Eyeglasses second is the first listed.
NCT06883032 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06883032 about?
NCT06883032 is a clinical study titled "Investigation of the Accuracy of an Automated Refractor to Provide Well-tolerated Eyeglass Prescriptions". At the New England College of Optometry in Boston, MA, subjects ages 18-65 who have received or are receiving treatment for refractive error who choose to enroll in the study will be evaluated using subjective refraction and automated refraction, by way of the QuickSee Plus refractor. Subjects will ...
What is the current status of trial NCT06883032?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2025-02-16. Estimated completion is 2025-02-28.
What conditions does trial NCT06883032 study?
This clinical trial studies the following conditions: Refractive Errors.
What interventions are being tested in trial NCT06883032?
The interventions under investigation include: AR Eyeglasses first, SR Eyeglasses second (OTHER), SR Eyeglasses first, AR Eyeglasses second (OTHER).
Who is sponsoring clinical trial NCT06883032?
This trial is sponsored by PlenOptika, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883032 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractive Errors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06883032's enrollment target sits among peer trials
92 6th of 14 higher than 9 of 14 other Refractive Errors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractive Errors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Performance of a Silicone Hydrogel Contact Lens Following One Night of Extended Wear
COMPLETED · NA
-
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
COMPLETED · NA
-
Clinical Performance of a Monthly Replacement Silicone Hydrogel Lens
COMPLETED · NA
-
DD T2 Daily Disposable Registration Trial
COMPLETED · NA
-
Clinical Assessment of a HYDRAGLYDE® Regimen
COMPLETED · NA
-
Assessing Fitting Guides in Alcon Multifocal Contact Lenses
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI